In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2002-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.46.6.1723-1727.2002PMID 12019081PMCID PMC127275
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature

  2004cited by this paper
• Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in Candida albicans Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected Patients

  2001influential reference
• Antifungal Susceptibility Testing: Practical Aspects and Current Challenges

  2001cited by this paper
• In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. andCryptococcus neoformans

  2001cited by this paper
• International Surveillance of Bloodstream Infections Due toCandida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program

  2001cited by this paper
• Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents

  2000cited by this paper
• Manual of Clinical Microbiology, 7th ed.

  2000cited by this paper
• Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

  2000cited by this paper
• In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, againstAspergillus and Candida

  2000cited by this paper
• Voriconazole: A New Triazole Antifungal

  2000cited by this paper
• Current and Emerging Azole Antifungal Agents

  1999cited by this paper
• In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America

  1999cited by this paper
• In Vitro Activity of a New Oral Triazole, BMS-207147 (ER-30346)

  1998cited by this paper
• Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B.

  1998cited by this paper
• National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species.

  1998cited by this paper
• In Vitro Activity of the New Triazole Voriconazole (UK-109,496) against Opportunistic Filamentous and Dimorphic Fungi and Common and Emerging Yeast Pathogens

  1998cited by this paper
• Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance

  1998cited by this paper
• National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program.

  1998cited by this paper
• In Vitro Susceptibilities of CandidaBloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole

  1998cited by this paper
• In Vitro Activities of Voriconazole (UK-109,496) and Four Other Antifungal Agents against 394 Clinical Isolates ofCandida spp

  1998cited by this paper
• National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic.

  1998cited by this paper
• International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and Antifungal Susceptibilities of Isolates Collected in 1997 in the United States, Canada, and South America for the SENTRY Program

  1998cited by this paper
• Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora

  1997cited by this paper
• In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection

  1997cited by this paper
• In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum

  1996cited by this paper
• Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis

  1996cited by this paper
• In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species

  1996cited by this paper
• detect amphotericin B-resistant Candida susceptibility testing : enhanced ability to macrodilution method for antifungal for Clinical Laboratory Standards broth Comparison of Etest and National Committee

  1995cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper
• Manual of clinical microbiology

  1975cited by this paper

• Distribution and prevalence of fungemia: a five-year retrospective multicentric survey in Venetian region, Italy

  2025cites this paper
• Antimicrobial effect of Streptococcus salivarius outer membrane-coated nanocomplexes against Candida albicans and oral candidiasis

  2023cites this paper
• In vitro antifungal activity of Morinda citrifolia (noni) extract against Candida albicans.

  2022cites this paper
• Hsp90 interaction networks in fungi—tools and techniques

  2021cites this paper
• Supramolecular Self-Assembly Built by Weak Hydrogen, Chalcogen, and Unorthodox Nonbonded Motifs in 4-(4-Chlorophenyl)-3-[(4-fluorobenzyl)sulfanyl]-5-(thiophen-2-yl)-4H-1,2,4-triazole, a Selective COX-2 Inhibitor: Insights from X-ray and Theoretical Studies

  2021cites this paper
• A Mycological and Molecular Epidemiologic Study on Onychomycosis and Determination In Vitro Susceptibilities of Isolated Fungal Strains to Conventional and New Antifungals

  2021cites this paper
• In Vitro activity of ravuconazole against Candida auris and vaginal candida isolates

  2021cites this paper
• Resistance of Candida albicans to antifungal drugs in Abidjan (Cote dIvoire)

  2020cites this paper
• Antifungal Susceptibility Profile of Candida Albicans Isolated from Vulvovaginal Candidiasis in Xinjiang Province of China

  2019cites this paper
• Evaluation of Susceptibility to Fluconazole and Voriconazole in Oral Candida glabrata Isolates from Drug Addicts

  2019cites this paper
• Relative Abundances of Candida albicans and Candida glabrata in In Vitro Coculture Biofilms Impact Biofilm Structure and Formation

  2018cites this paper
• Efficacy and safety of fosravuconazole L‐lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double‐blind, randomized phase III study

  2018cites this paper
• Clinical Drug–Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects

  2018cites this paper
• Liposomal and Deoxycholate Amphotericin B Formulations: Effectiveness against Biofilm Infections of Candida spp.

  2017cites this paper
• Antifungal activity in vitro and in vivo of a salmon protamine peptide and its derived cyclic peptide against Candida albicans

  2017cites this paper
• Translocation of cell‐penetrating peptides into Candida fungal pathogens

  2017cites this paper
• Susceptibility pattern of anti-candida drugs in the pediatric patients with acute leukemia

  2017cites this paper
• Title : Antifungal activity in vitro and in vivo of a salmon protamine peptide and its derived cyclic peptide against Candida albicans Running title : Antifungal activity of protamine derived peptides

  2016cites this paper
• Intrastromal voriconazole: the next effective adjunctive treatment for recalcitrant keratomycosis.

  2016cites this paper
• Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications.

  2016cites this paper
• Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis.

  2016cites this paper
• Synthesis and Antifungal Screening of 2‐(2‐Aryl‐4‐methyl‐thiazol‐5‐yl)‐5‐((2‐aryl/benzylthiazol‐4‐yl)methyl)‐1,3,4‐oxadiazole Derivatives

  2016cites this paper
• Past, Present, and Future of Antifungal Drug Development

  2016cites this paper
• Oral Antifungal Drugs in the Treatment of Dermatomycosis.

  2016cites this paper
• 38 – Opportunistic Mycoses

  2016cites this paper
• Prevalence of oral Candidiasis and Risk Factors in Diabetic Pateints

  2015influential citation
• A n t i f u n g a l A g e n t s Spectrum of Activity, Pharmacology, and Clinical Indications

  2015cites this paper
• Candida glabrata candidemia: An emerging threat in critically ill patients

  2015cites this paper
• In vitro susceptibility of filamentous fungi from mycotic keratitis to azole drugs.

  2015cites this paper
• Spectrum of Activity, Pharmacology, and Clinical Indications

  2015cites this paper
• PROSPECTIVE STUDY OF EFFECTIVENESS OF INTRASTROMAL VORICONAZOLE INJECTION IN THE MANAGEMENT OF DEEP NON HEALING FUNGAL CORNEAL ULCER AS AN ADJUNCTIVE THERAPY

  2015cites this paper
• Efficacy of ravuconazole in a murine model of vaginitis by Candida albicans.

  2015cites this paper
• Cytotoxic Effect of Voriconazole on Human Corneal Epithelial Cells

  2015cites this paper
• Madurella mycetomatis Is Highly Susceptible to Ravuconazole

  2014cites this paper
• In vitro activities of amphotericin B deoxycholate and liposomal amphotericin B against 604 clinical yeast isolates

  2014influential citation
• [In vitro antifungal activity of ravuconazole against isolates of dermatophytes and Candida species from patients with dermatomycoses].

  2014cites this paper
• Phenotypic and molecular genetic profiles of fluconazole and voriconazole sensitive versus resistant candida spp

  2014cites this paper
• Voriconazole Disposition After Single and Multiple, Oral Doses in Healthy, Adult Red-tailed Hawks (Buteo jamaicensis)

  2014cites this paper
• Pharmacokinetics and Pharmacodynamics of Antibacterials, Antifungals, and Antivirals Used Most Frequently in Neonates and Infants

  2014cites this paper
• Some new azole type heterocyclic compounds as antifungal agents

  2014cites this paper
• 皮膚真菌症患者検体から分離された皮膚糸状菌および Candida 属菌に対する ravuconazole の in vitro 抗真菌活性:皮膚真菌症の治療に適用承認されている２種の経口抗真菌薬との比較

  2014cites this paper
• Some new azole type heterocyclic compounds as antifungal agents

  2014cites this paper
• Pharmacokinetics and Pharmacodynamics of Antibacterials, Antifungals, and Antivirals Used Most Frequently in Neonates and Infants Jessica K. RobertsChris StockmannJonathan E. Constance • Justin StiersMichael G. SpigarelliRobert M. Ward •

  2014cites this paper
• How to treat severe infections in critically ill neutropenic patients?

  2014cites this paper
• Yeast Colonization and Drug Susceptibility Pattern in the Pediatric Patients With Neutropenia

  2014cites this paper
• Diagnosis and Treatment of Invasive Fungal Infections Focus on Liposomal Amphotericin B

  2013cites this paper
• Evaluation of pathogenicity of Candida albicans in germination-ready states using a silkworm infection model.

  2013cites this paper
• Corneal stromal abscessation in two horses treated with intracorneal and subconjunctival injection of 1% voriconazole solution.

  2013cites this paper
• Recent advances in the treatment of life-threatening, invasive fungal infections

  2013cites this paper
• The biology and chemistry of antifungal agents: a review.

  2012cites this paper
• Facultative Sterol Uptake in an Ergosterol-Deficient Clinical Isolate of Candida glabrata Harboring a Missense Mutation in ERG11 and Exhibiting Cross-Resistance to Azoles and Amphotericin B

  2012influential citation
• Risk factors for candidemia with non-albicans Candida spp. in intensive care unit patients with end-stage renal disease on chronic hemodialysis.

  2012cites this paper
• Two Clinical Isolates of Candida glabrata Exhibiting Reduced Sensitivity to Amphotericin B Both Harbor Mutations in ERG2

  2012cites this paper
• Epidemiology Incidence and Risk Factors for Invasive Candidiasis in High-Risk Patients

  2012cites this paper
• Anidulafungin, a New Echinocandin

  2012cites this paper
• Species distribution and in vitro susceptibility to three antifungal triazoles of clinical Candida isolates from a five-year nation-wide survey in Japan

  2012cites this paper
• Utility of Antifungal Susceptibility Testing and Clinical Correlations

  2012cites this paper
• Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use

  2012cites this paper
• Interactions of Yeasts, Moulds, and Antifungal Agents

  2012cites this paper
• Aloe vera extract reduces both growth and germ tube formation by Candida albicans

  2012cites this paper
• Antifungal Therapy in The ICU: The Bug, the Drug, and the Mug

  2011cites this paper
• In Vitro Antifungal Activity of Dihydroxyacetone Against Causative Agents of Dermatomycosis

  2011cites this paper
• Advances in synthetic approach to and antifungal activity of triazoles

  2011cites this paper
• Pharmacokinetics of Voriconazole Administered Concomitantly with

  2011cites this paper
• Newer antifungal agents

  2011cites this paper
• Newer antifungal agents.

  2011cites this paper
• Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations

  2011cites this paper
• Mucocutaneous and Deeply Invasive Candidiasis

  2011cites this paper
• New-generation triazole antifungal drugs: review of the Phase II and III trials

  2011cites this paper
• Pharmacokinetics of Voriconazole Administered Concomitantly with Fluconazole and Population-Based Simulation for Sequential Use

  2011cites this paper
• Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.

  2011cites this paper
• Candida albicans growth and germ tube formation can be inhibited by simple diphenyl diselenides [(PhSe)2, (MeOPhSe)2, (p‐Cl‐PhSe)2, (F3CPhSe)2] and diphenyl ditelluride

  2011cites this paper
• Treatment Strategies for Invasive Aspergillosis in Neutropenic Patients: Voriconazole or Liposomal Amphotericin-B?

  2011cites this paper
• Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections

  2010cites this paper
• Concern Widens over the Quality, Safety and Effi cacy of Drugs Sold in Hong Kong

  2010cites this paper
• Antibacterial, antifungal, and antiviral activities of some flavonoids.

  2010cites this paper
• Hemolytic activity and production of germ tubes related to pathogenic potential of clinical isolates of Candida albicans

  2010cites this paper
• In vitro activity of fluconazole and voriconazole against clinical isolates of Candida spp. by E-test method.

  2010cites this paper
• Epidemiology of invasive candidiasis

  2010cites this paper
• Determination of Voriconazole and its Degradation products in Pharmaceutical formulations using High Performance Liquid Chromatography with Ultra-Violet Detection

  2010cites this paper
• ORAL CANDIDIASIS: A REVIEW

  2010cites this paper
• Epidemiology of Invasive Mycoses in North America

  2010influential citation
• Managing Infections in Patients With Hematological Malignancies

  2010cites this paper
• Susceptibility of Candida albicans to common and novel antifungal drugs, and relationship between the mating type locus and resistance, in Lebanese hospital isolates

  2009cites this paper
• Fungal and Parasitic Infections

  2009cites this paper
• In vitro antifungal activity of 2‐(2′‐hydroxy‐5′‐aminophenyl)benzoxazole in Candida spp. strains

  2009cites this paper
• CHAPTER 30 – Fungal infections of the eye

  2009cites this paper
• A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.

  2009influential citation
• The photodynamic effect of methylene blue and toluidine blue on Candida albicans is dependent on medium conditions

  2009cites this paper
• Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.

  2009cites this paper
• New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance

  2009cites this paper
• Phenotypical characterization of Candida spp. isolated from crop of parrots (Amazona spp.).

  2009cites this paper
• Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B

  2009cites this paper
• New generation azole antifungals in clinical investigation

  2009cites this paper
• Mutants with heteroresistance to amphotericin B and fluconazole in Candida

  2009cites this paper
• Recent Approaches to Antifungal Therapy for Invasive Mycoses

  2009cites this paper
• Diagnostik und Therapie der Keratomykose

  2009cites this paper
• Chapter 4 Fungal and Parasitic Infections

  2009cites this paper
• Current challenges in the management of invasive fungal infections

  2008cites this paper
• Pharmacokinetic–pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies

  2008cites this paper